Holen Sie sich die Stockscreener-App
0.7961
0.35%
-0.00285
Schlusskurs vom Vortag:
$0.7989
Offen:
$0.78
24-Stunden-Volumen:
1.09M
Relative Volume:
0.53
Marktkapitalisierung:
$27.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.34M
KGV:
-1.1421
EPS:
-0.697
Netto-Cashflow:
$-15.59M
1W Leistung:
+12.63%
1M Leistung:
-51.75%
6M Leistung:
-49.93%
1J Leistung:
-74.65%
1-Tages-Spanne:
$0.7482
$0.8099
1-Wochen-Bereich:
$0.6601
$0.814
52-Wochen-Spanne:
$0.54
$3.48
Heartbeam Inc Stock (BEAT) Company Profile
Firmenname
Heartbeam Inc
Sektor
Branche
Telefon
408-899-4443
Adresse
2118 WALSH AVE., SUITE 210, SANTA CLARA
Vergleichen Sie BEAT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAT
Heartbeam Inc
|
0.7961 | 27.52M | 0 | -20.34M | -15.59M | -0.697 |
|
VEEV
Veeva Systems Inc
|
232.04 | 39.30B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
76.28 | 13.71B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
45.62 | 8.60B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
93.25 | 7.87B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
35.34 | 6.23B | 11.99B | 24.18M | 234.31M | 0.2956 |
Heartbeam Inc Stock (BEAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Eingeleitet | Roth Capital | Buy |
| 2020-09-11 | Eingeleitet | Needham | Buy |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Neutral |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2019-08-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-04-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-07-26 | Bestätigt | Lake Street | Buy |
| 2018-04-26 | Bestätigt | The Benchmark Company | Buy |
| 2018-02-23 | Bestätigt | Dougherty & Company | Buy |
| 2017-11-08 | Bestätigt | Dougherty & Company | Buy |
| 2017-10-26 | Eingeleitet | Raymond James | Outperform |
| 2017-10-24 | Eingeleitet | SunTrust | Buy |
| 2017-08-09 | Bestätigt | Dougherty & Company | Buy |
| 2017-07-19 | Bestätigt | The Benchmark Company | Buy |
| 2017-04-11 | Bestätigt | Dougherty & Company | Buy |
| 2016-12-02 | Eingeleitet | Dougherty & Company | Buy |
| 2016-09-13 | Eingeleitet | Sidoti | Buy |
| 2016-08-03 | Bestätigt | The Benchmark Company | Buy |
| 2015-07-28 | Bestätigt | Dougherty & Company | Buy |
| 2013-10-24 | Eingeleitet | The Benchmark Company | Buy |
| 2013-08-21 | Eingeleitet | Dougherty & Company | Buy |
Alle ansehen
Heartbeam Inc Aktie (BEAT) Neueste Nachrichten
HC Wainwright & Co. Initiates Coverage of HeartBeam (BEAT) with Buy Recommendation - Nasdaq
HeartBeam (BEAT) Receives 'Buy' Rating from HC Wainwright & Co. - GuruFocus
HC Wainwright Initiates HeartBeam at Buy With $2.50 Price Target - marketscreener.com
HeartBeam initiated with a Buy at H.C. Wainwright - TipRanks
Will HeartBeam Inc stock deliver shareholder valueWeekly Investment Report & Stepwise Entry/Exit Trade Alerts - BỘ NỘI VỤ
How institutional buying supports HeartBeam Inc. stockEarnings Risk Summary & Daily Technical Forecast Reports - Newser
Why hedge funds are buying HeartBeam Inc. stockEarnings Miss & Technical Entry and Exit Alerts - Newser
Will HeartBeam Inc. stock maintain dividend yieldMarket Rally & Fast Exit Strategy with Risk Control - Newser
What is the fair value of HeartBeam Inc. Equity Warrant stock nowQuarterly Trade Summary & Advanced Swing Trade Entry Alerts - Newser
HeartBeam Pursues Regulatory Path After FDA Decision on ECG Software - citybuzz
HeartBeam (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software - Digital Journal
HeartBeam (BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software - NewMediaWire
HeartBeam Outlines Regulatory Strategy Following FDA Decision on ECG Software - citybuzz
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Will HeartBeam Inc. Equity Warrant stock outperform tech sector in 2025Breakout Watch & Fast Gain Swing Alerts - moha.gov.vn
Biotech Minors Make Major Moves On FDA News And Stock Sales - Finimize
HeartBeam’s Strategic Path to Overcome Regulatory Challenges and Secure Buy Rating - TipRanks
Crude Oil Gains 1%; Tilray Brands Shares Plunge - Benzinga
Nasdaq Rises 100 Points; Chagee Shares Gain After Q3 Results - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
HeartBeam Outlines Regulatory Path Following FDA NSE Decision On 12-Lead ECG Synthesis Software - Nasdaq
Is HeartBeam Inc. stock dividend yield sustainableGold Moves & Safe Capital Growth Plans - BỘ NỘI VỤ
What's Behind HeartBeam's Over 40% After-Hours Surge? - Benzinga
HeartBeam, Inc. (BEAT) Stock: Soars as FDA Appeal Strategy Sparks Investor Optimism - parameter.io
HeartBeam pursues multiple options after FDA rejection of ECG software By Investing.com - Investing.com Nigeria
Heartbeam provides update on regulatory path following FDA decision on 12-lead ECG synthesis software application - marketscreener.com
Heartbeam Provides Update On Regulatory Path Following FDA Decision On 12-Lead ECG Synthesis Software Application - TradingView
HeartBeam pursues multiple options after FDA rejection of ECG software - Investing.com
HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application - The AI Journal
HeartBeam stock surges after FDA signals path forward on ECG software - Investing.com Nigeria
HeartBeam updates regulatory strategy for 12-lead ECG Synthesis Software - TipRanks
HeartBeam stock surges after FDA signals path forward on ECG software By Investing.com - Investing.com South Africa
HeartBeam : Earnings Documents - marketscreener.com
HeartBeam, Inc. Earnings Call Highlights Progress and Challenges - MSN
Is HeartBeam Inc Equity Warrant a good long term investmentMerger & Acquisition Updates & Hidden Gems with Outstanding Profit Margins - earlytimes.in
HeartBeam Stock Slumps After FDA Refuses Clearance For ECG Software - MSN
HeartBeam, Inc. (NASDAQ:BEAT) Q3 2025 Earnings Call Transcript - MSN
FDA Letter, AI Worries, And Weak Earnings Rattle Key Stocks - Finimize
Roth sees potential FDA clearance for HeartBeam despite letter - TipRanks
HeartBeam Shares Fall After 510(k) Rejection From US FDA for ECG Software Application - MarketScreener
HeartBeam sinks after ‘Not Substantially Equivalent’ letter from FDA - TipRanks
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
HeartBeam says received NSE letter from FDA for 12-lead ECG synthesis softwareSEC filing - marketscreener.com
HeartBeam receives FDA NSE letter for ECG software, evaluates 3D ECG system launch - Investing.com Nigeria
HeartBeam receives FDA NSE letter for ECG software, evaluates 3D ECG system launch By Investing.com - Investing.com South Africa
HeartBeam Receives FDA NSE Letter for ECG Software - TradingView
[8-K] HeartBeam, Inc. Reports Material Event | BEAT SEC FilingForm 8-K - Stock Titan
How rising interest rates impact HeartBeam Inc. stockEarnings Risk Summary & Reliable Trade Execution Plans - newser.com
Will HeartBeam Inc. Equity Warrant stock continue upward momentumProduct Launch & Fast Exit/Entry Strategy Plans - newser.com
Can HeartBeam Inc. stock surprise with earnings upsideJuly 2025 Action & Weekly Top Stock Performers List - newser.com
Finanzdaten der Heartbeam Inc-Aktie (BEAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.77%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):